Search Results - "CERNY, T"

The Range of Neurological Complications in Chikungunya Fever by Cerny, T., Schwarz, M., Schwarz, U., Lemant, J., Gérardin, P., Keller, E.

“…Background Chikungunya fever is a globally spreading mosquito-borne disease that shows an unexpected neurovirulence. Even though the neurological complications…”
Get full text

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia cachexia: a randomised, placebo-controlled, double-blind, double-crossover study by Strasser, F, Lutz, T A, Maeder, M T, Thuerlimann, B, Bueche, D, Tschöp, M, Kaufmann, K, Holst, B, Brändle, M, von Moos, R, Demmer, R, Cerny, T

“…Twenty-one adult patients were randomised to receive ghrelin on days 1 and 8 and placebo on days 4 and 11 or vice versa, given intravenously over a 60-min…”
Get full text

Fear, Pain, Denial, and Spiritual Experiences in Dying Processes by Renz, M., Reichmuth, O., Bueche, D., Traichel, B., Mao, M. Schuett, Cerny, T., Strasser, F.

“…Purpose: Approaching death seems to be associated with physiological/spiritual changes. Trajectories including the physical–psychological–social–spiritual…”
Get full text

Effects of land-use changes on plant functional and taxonomic diversity along a productivity gradient in wet meadows by Janeček, Š., de Bello, F., Horník, J., Bartoš, M., Černý, T., Doležal, J., Dvorský, M., Fajmon, K., Janečková, P., Jiráská, Š., Mudrák, O., Klimešová, J.

“…Questions: To what extent do changes in management (abandonment and fertilization) affect plant functional and taxonomic diversity in wet meadow communities?…”
Get full text

Patient Preference Studies for Advanced Prostate Cancer Treatment Along the Medical Product Life Cycle: Systematic Literature Review by Menges, Dominik, Piatti, Michela C, Cerny, Thomas, Puhan, Milo A

“…Background: Patient preference studies can inform decision-making across all stages of the medical product life cycle (MPLC). The treatment landscape for…”
Get full text

The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action by Joerger, M, Omlin, A, Cerny, T, Früh, M

“…Pemetrexed is a newer antifolate drug that has been approved as first-line treatment for patients with advanced non-squamous, non-small cell lung cancer…”
Get more information

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non‐small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices by Ess, S.M., Herrmann, C., Frick, H., Krapf, M., Cerny, T., Jochum, W., Früh, M.

“…In order to improve outcomes, identification of the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) genes has become crucial in…”
Get full text

Elevated preoperative CEA is associated with worse survival in stage I–III rectal cancer patients by Tarantino, I, Warschkow, R, Worni, M, Merati-Kashani, K, Köberle, D, Schmied, B M, Müller, S A, Steffen, T, Cerny, T, Güller, U

“…Background: The objective of this investigation was to assess whether preoperative carcinoembryonic antigen (CEA) level is an independent predictor of overall…”
Get full text

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study by Joerger, M., Schaer-Thuer, C., Koeberle, D., Matter-Walstra, K., Gibbons-Marsico, J., Diem, S., Thuerlimann, B., Cerny, T.

“…Purpose Prevalence data on the off-label use (OLU) of anticancer drugs are limited despite OLU being controversial for medical, pharmaco-economic, and ethical…”
Get full text

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy by Joerger, M., Huitema, A. D. R., Boot, H., Cats, A., Doodeman, V. D., Smits, P. H. M., Vainchtein, L., Rosing, H., Meijerman, I., Zueger, M., Meulendijks, D., Cerny, T. D., Beijnen, J. H., Schellens, J. H. M.

“…Purpose This work was initiated to extend data on the effect of pharmacogenetics and chemotherapy pharmacokinetics (PK) on clinical outcome in patients with…”
Get full text

Remission of diabetes while on sunitinib treatment for renal cell carcinoma by Templeton, A., Brändle, M., Cerny, T., Gillessen, S.

Get full text

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial by Joerger, M, Huitema, A D R, Krähenbühl, S, Schellens, J H M, Cerny, T, Reni, M, Zucca, E, Cavalli, F, Ferreri, A J M

“…Background: This analysis was initiated to define the predictive value of the area under the curve of high-dose methotrexate (AUC HD-MTX ) in patients with…”
Get full text

Spiritual Experiences of Transcendence in Patients With Advanced Cancer by Renz, M., Mao, M. Schuett, Omlin, A., Bueche, D., Cerny, T., Strasser, F.

“…Purpose: Spirituality encompasses a wide range of meanings between holistic wellbeing and mysticism. We explored advanced cancer patients' spiritual…”
Get full text

Anti-nicotine vaccination: where are we? by Cerny, T

“…Nicotine is the main substance responsible for dependence on tobacco-containing, products, which have a heavy impact on the public health of developed as well…”
Get more information

Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study by Strasser, F, Binswanger, J, Cerny, T, Kesselring, A

“…Background: Anorexia/cachexia is a frequent complication of advanced cancer with poorly understood psychosocial impact or eating-related distress (ERD) on both…”
Get full text

PV-0123: Gender and secondary malignancies in rectal cancer patients with and without radiation therapy by Warschkow, R, Güller, U, Cerny, T, Schmied, B.M, Plasswilm, L, Putora, P.M

Get full text

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study by BETTICHER, D. C, HSU SCHMITZ, S.-F, SPILIOPOULOS, A, STAHEL, R, WEDER, W, STUPP, R, EGLI, F, FURRER, M, HONEGGER, H, WERNLI, M, CERNY, T, RIS, H.-B, TÖTSCH, M, HANSEN, E, JOSS, C, VON BRIEL, C, SCHMID, R. A, PLESS, M, HABICHT, J, ROTH, A. D

“…The aim was to investigate the efficacy of neoadjuvant docetaxel-cisplatin and identify prognostic factors for outcome in locally advanced stage IIIA (pN2 by…”
Get full text

Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK) by Ghielmini, M., Rufibach, K., Salles, G., Leoncini-Franscini, L., Léger-Falandry, C., Cogliatti, S., Fey, M., Martinelli, G., Stahel, R., Lohri, A., Ketterer, N., Wernli, M., Cerny, T., Schmitz, S.-F. Hsu

“…Background: Predictive factors of rituximab efficacy and its effect on the immune system are still not defined. Patients and methods: Three hundred and six…”
Get full text

Erlotinib has Comparable Clinical Efficacy to Chemotherapy In Pretreated Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Propensity-adjusted, Outcomes Research-based Study by Neumair, P, Joos, L, Warschkow, R, Dutly, A, Ess, S, Hitz, F, Früh, M, Brutsche, M, Baty, F, Krähenbühl, S, Cerny, T, Joerger, M

“…Highlights • Integration of erlotinib in EGFR wildtype, advanced NSCLC has become controversial. • This study accounted for erlotinib being preferentially…”
Get full text

Discrete Improvement in Racial Disparity in Survival among Patients with Stage IV Colorectal Cancer: a 21-Year Population-Based Analysis by Castleberry, A. W., Güller, U., Tarantino, I., Berry, M. F., Brügger, L., Warschkow, R., Cerny, T., Mantyh, C. R., Candinas, D., Worni, M.

“…Purpose Recently, multiple clinical trials have demonstrated improved outcomes in patients with metastatic colorectal cancer. This study investigated if the…”
Get full text